Sykes Electrolyte Solution Compound Sodium Lactate Hartmanns by is a Animal medication manufactured, distributed, or labeled by Sypharma Pty Ltd. Drug facts, warnings, and ingredients follow.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmanns Solution) is a sterile, non-pyrogenic solution intended for fluid and electrolyte replenishment in single dose containers. May be administered intravenously, subcutaneously or intraperitoneally (except in horses) using aseptic technique. It contains no antimicrobial agents. Discard any unused portion. Composition, osmolarity, pH and ionic concentration are shown in Table 1.
Table 1
Composition (g/L) | Sodium Chloride | Potassium Chloride | Calcium Chloride | Sodium Lactate* | |
6.0 | 0.40 | 0.28 | 3.24 | ||
Ionic Concentration (mEq/L) | Sodium | Potassium | Calcium | Chloride | Lactate |
131 | 5 | 2 | 111 | 29 |
*Sodium Lactate USP (S)-enantiomer
Osmolarity (mOsmol/L) (calc): 280mOsmol per litre
pH: 6.5 (limit 6.0 to 7.0)
The container is free of PVC and phthalates. The container meets the requirements of USP and is registered with US FDA.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) is contraindicated in patients with a known hypersensitivity to sodium lactate; congestive heart failure or severe impairment of renal function; clinical states in which the administration of sodium and chloride is detrimental.
The introduction of additives to any solution, regardless of type of container, requires special attention to ensure that no incompatibilities result. While some incompatibilities are readily absorbed, one must be aware that subtle physical, chemical and pharmacological incompatibilities can occur. The medical literature, the package insert and other available sources of information should be reviewed for thorough understanding of possible incompatibilities.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema and sodium retention.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should not be administered simultaneously with blood through the same administration set because of likelihood of coagulation.
The intravenous administration of Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, over-hydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overloading causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.
In patients with diminished renal function, administration of Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) may result in sodium or potassium retention.
Do not administer to horses by intraperitoneal injection. Do not administer to animals with inadequate renal function. Not for use in lactic acidosis.
Adverse reactions may occur due to the solution or the technique of administration including fever response, infection at the site of injection or allergic reactions. Prolonged intravenous infusion of this type of product may cause venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.
If an adverse reaction does occur, discontinue the infusion and evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
This is a single dose unit. It contains no preservatives. Use entire contents when first opened.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged therapy or whenever the condition of the patient warrants such evaluation.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) should be used with caution. Excess administration may result in metabolic alkalosis.
Do not administer unless solution is clear and both seal and container are intact.
Solution must be warmed to body temperature prior to administration and administered at a slow rate. Use solution promptly following initial entry.
Reactions which may occur because of the solution or the technique of administration, include febrile response, infection at the site of injection, extravasation, and hypervolemia.
If an adverse reaction does occur, discontinue the infusion and evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
To be used as directed by a licensed veterinarian. The dosage of the Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) is dependent upon the age, weight and clinical conditions of the patient as well as laboratory determinations. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
For use in one patient on one occasion only. Discard any unused portion. Care should be taken with administration technique to avoid administration site reactions and infection.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with Pharmacist, if available. If, in the informed judgement of the doctor, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
Sykes Electrolyte Solution Compound Sodium Lactate (Hartmann’s Solution) in plastic container is available as follows:
Size (mL) |
Item Code |
NDC |
250 |
FPHARTUS25 |
86043-1001-1 |
500 |
FPHARTUS50 |
86043-1001-2 |
1000 |
FPHARTUS01 |
86043-1001-3 |
3000 |
FPHARTUS03 |
86043-1001-4 |
5000 |
FPHARTUS05 |
86043-1001-5 |
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (30°C/86°F). Protect from freezing.
To Open
Tear overwrap at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below:
Preparation for Administration
To Add Medication
WARNING: Additives may be incompatible.
To add medication before solution administration
To add medication during solution administration
CAUTION: FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN.
Made in Australia
Manufactured and distributed by:
Sypharma Pty Ltd
27 Healey Road Dandenong
Victoria 3175 Australia
For customer service email:
customerservice@sypharma.com.au
Version: US_01
SYKES ELECTROLYTE SOLUTION COMPOUND SODIUM LACTATE HARTMANNS
sodium chloride, potassium chloride, sodium lactate and calcium chloride solution |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
Labeler - Sypharma Pty Ltd (753786292) |
Registrant - Sypharma Pty Ltd (753786292) |